C4X Discovery Holdings PLC Posting of 2023 Annual Report and Notice of AGM (1947X)
18 Diciembre 2023 - 9:31AM
UK Regulatory
TIDMC4XD
RNS Number : 1947X
C4X Discovery Holdings PLC
18 December 2023
C4X Discovery Holdings plc
("C4XD", "C4X Discovery" or the "Company")
Posting of 2023 Annual Report and Notice of AGM
18 December 2023 - C4X Discovery Holdings plc (AIM: C4XD), a
pioneering Drug Discovery company, announces that it has today
published and posted to shareholders the Annual Report and Accounts
for the year ended 31 July 2023 and Notice of the Annual General
Meeting ("AGM") which will be held at Panmure Gordon, 40
Gracechurch Street, EC3V 0BT , on 23 January 2024 at 11.30 a.m.
(GMT).
The Annual Report and Accounts and Notice of AGM are also
available to view on, and download from, the Company's website at
www.c4xdiscovery.com
- Ends -
Contacts
C4X Discovery Holdings
Mo Noonan, Communications +44 (0)787 6444977
Panmure Gordon (UK) Limited (NOMAD and
Broker)
Freddy Crossley, Emma Earl (Corporate
Finance) +44 (0)20 7886 2500
Rupert Dearden (Corporate Broking)
C4X Discovery Media - Consilium Strategic
Communications
Mary-Jane Elliott, Chris Gardner, Matthew
Neal +44 (0)203 709 5700
Notes to Editors:
About C4X Discovery
C4X Discovery ("C4XD") is a pioneering Drug Discovery company,
combining scientific expertise with cutting-edge Drug Discovery
technologies to efficiently deliver world--leading medicines. We
have a highly valuable and differentiated approach to Drug
Discovery through our enhanced candidate molecule design and
patient stratification capabilities, generating small molecule drug
candidates across multiple disease areas focused on
immuno-inflammation. Our commercially attractive portfolio ranges
from early-stage target opportunities to late-stage Drug Discovery
programmes and we have three commercially partnered programmes with
one candidate in clinical development.
For more information visit us at www.c4xdiscovery.com or follow
us on twitter @C4XDiscovery.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOATPBATMTJBBMJ
(END) Dow Jones Newswires
December 18, 2023 10:31 ET (15:31 GMT)
C4x Discovery (LSE:C4XD)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
C4x Discovery (LSE:C4XD)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024